Organon & Co. (OGN)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 18.52 |
| Open | 18.44 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1800 |
| Day's range | 18.11 - 18.75 |
| 52-week range | 10.84 - 24.79 |
| Volume | |
| Avg. volume | 2,351,717 |
| Market cap | 4.783B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 4.69 |
| EPS (TTM) | 3.99 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 1.12 (5.99%) |
| Ex-dividend date | 23 Feb 2024 |
| 1y target est | 21.50 |
Business WireOrganon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
Business WirePhase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
Business WireOrganon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
JERSEY CITY, N.J., February 20, 2024--Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
© 2024 Yahoo. All rights reserved.